Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on LinkedIn and X - @MolecularPrtnrs
Company profile
Ticker
MOLN, MLLCF
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
6-K
Molecular Partners Publishes Invitation to Annual General Meeting 2024
26 Mar 24
20-F
2023 FY
Annual report (foreign)
14 Mar 24
6-K
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
6-K
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
5 Jan 24
6-K
Current report (foreign)
11 Dec 23
6-K
Current report (foreign)
2 Nov 23
6-K
Current report (foreign)
26 Oct 23
6-K
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
24 Aug 23
S-8
Registration of securities for employees
28 Jun 23
6-K
Current report (foreign)
12 May 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
15.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 3.91 bn |
Total shares | 5.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 4.51 mm | $0.00 |
BVF | 443.22 k | $1.77 bn |
Suvretta Capital Management | 400.00 k | $1.66 bn |
Tang Capital Management | 100.00 k | $414.00 mm |
Susquehanna International | 16.58 k | $66.13 mm |
MS Morgan Stanley | 367.00 | $1.52 mm |
Rhumbline Advisers | 269.00 | $1.07 mm |
Qube Research & Technologies | 16.00 | $64.00 k |
Proequities | 0.00 | $0.00 |
News
Molecular Partners Announces Publication In Cancer Immunology Research Of Preclinical Data Supporting MP0533's Proposed Mechanism Of Action
29 Apr 24
Molecular Partners FY 2023 GAAP EPS $(2.13) Misses $(2.00) Estimate, Sales $7.894M Beat $5.333M Estimate
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
Press releases
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action
29 Apr 24
Life Science Cares Launches in Switzerland
19 Apr 24
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
17 Apr 24
Molecular Partners Publishes Invitation to Annual General Meeting 2024
26 Mar 24
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
14 Mar 24